HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
ID: 353592Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $100K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353592

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at advancing research to identify new pain targets within the understudied druggable proteome. This initiative invites applications for pilot projects under the R03 Small Grant Program, providing up to $100,000 for projects lasting one year, focused on generating preliminary data on specified understudied proteins relevant to pain management without involving clinical trials. This funding is critical in addressing the public health crisis related to opioid addiction and the need for effective pain management solutions, encouraging diverse participation and collaboration among researchers. Interested applicants must submit their proposals electronically by July 16, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-197-Full-Announcement.html
    PAR-24-197.html
    The Department of Health and Human Services is offering funding opportunities through the HEAL Initiative aimed at advancing research to identify new pain targets within the understudied druggable proteome. Specifically, this funding opportunity focuses on the R03 Small Grant Program, offering up to $100,000 for pilot projects lasting one year. Eligible institutions can apply to generate preliminary data on the role of specified understudied proteins in pain management without involving clinical trials. The initiative encourages diverse participation and collaboration among researchers while providing a platform to elucidate protein functions critical for developing novel pain therapies. Key proteins eligible for study have low prior research engagement, presenting significant potential for innovations in treating pain. Additionally, all funded projects must comply with rigorous data management and sharing requirements to maximize research impact. The application submission process will be conducted electronically, and proposals will be peer-reviewed for scientific merit, with a focus on their relevance, significance, innovation, and methodological approach. This opportunity is crucial in addressing the ongoing public health crisis related to opioid addiction and the need for effective pain management solutions.
    Similar Opportunities
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at identifying new druggable targets for pain related to understudied proteins. This initiative invites pilot projects that focus on generating preliminary data on specific eligible proteins, particularly those with a PubMed score of less than 10, which are considered understudied and may lead to innovative pain treatments. The funding opportunity, which provides up to $100,000 for a one-year project, emphasizes the importance of diversity in applicant teams and requires coordination among grant recipients. Interested applicants should note that the application submission period begins on January 16, 2025, and clinical trials are not permitted under this grant. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-154.html.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative to support the development of non-addictive analgesic therapeutics, specifically small molecules and biologics, aimed at treating pain. The initiative seeks to accelerate the optimization and transition of promising therapeutic candidates to Phase I clinical trials, requiring applicants to demonstrate a compelling biological rationale and suitable assays for their projects. This funding is crucial for addressing the needs of over 25 million Americans suffering from chronic pain while providing alternatives to opioids. Approximately $11 million is anticipated for distribution across four awards in FY 2024, with applications due by January 24, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management," aimed at addressing the national opioid public health crisis. This initiative encourages small businesses to develop innovative, non-addictive therapies and technologies for improved pain management, including new medications, pain-assessment devices, and treatment strategies for chronic pain. The funding available includes up to $275,766 for Phase I and $1,838,436 for Phase II grants, with applications due by April 4, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices," aimed at addressing the opioid epidemic by promoting innovative research into alternative pain management solutions. This initiative seeks interdisciplinary research teams composed of multiple Principal Investigators (PDs/PIs) to explore the mechanisms of action of FDA-approved medical devices designed for pain relief, with the goal of optimizing therapeutic outcomes and enhancing understanding of device-based therapies. With over 25 million Americans suffering from chronic pain, this funding is critical for developing safe and effective pain treatment options that minimize addiction risks. Interested applicants can apply for grants with an award ceiling of $1.5 million, and proposals are due by June 9, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-028.html.
    HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at developing innovative therapies and technologies for enhanced pain management. This initiative specifically seeks applications from small businesses focused on creating non-addictive pain treatment alternatives, objective pain measurement tools, and new screening methodologies to address the national opioid crisis. With an annual funding projection of up to $8 million for 5-15 awards, eligible applicants must be U.S. small businesses, and the application deadline is set for April 4, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-006.html.
    HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the HEAL Initiative: Pain Research Enhancement Program (PREP), a federal grant aimed at supporting pain research projects from R15-eligible institutions. This initiative seeks to promote rigorous basic and mechanistic pain research, foster interdisciplinary collaborations, and enhance the research environment for health professional trainees and students. The program is crucial for diversifying the pain research workforce and advancing understanding of pain mechanisms, with funding available up to $375,000 over a maximum three-year period. Applications will be accepted starting October 18, 2024, with a deadline of November 19, 2024, and interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the HEAL Initiative: Pain Research Enhancement Program (PREP), a federal grant aimed at supporting rigorous basic and mechanistic pain research at R15-eligible institutions. This initiative seeks to foster interdisciplinary partnerships between eligible Principal Investigators (PIs) and other U.S. domestic entities, while enhancing the research environment for health professional trainees and students through active engagement in pain research projects. Grants of up to $375,000 are available for a maximum duration of three years, with applications due by 5:00 PM local time on November 23, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage for more details.
    HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative for the development of clinical-grade diagnostic and therapeutic devices aimed at treating pain and addressing opioid use disorder (OUD). This grant seeks to support the creation of non-addictive device-based technologies, advancing them from early development to preclinical stages suitable for FDA approval, with a focus on demonstrating treatment efficacy through credible neural targets. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, for-profit entities, and tribal governments, with funding available for up to three years and a maximum budget of $750,000 annually. Interested parties should note that the application deadline is June 17, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.